Pregnancy and preeclampsia studies

Review of machine learning techniques for early diagnosis of placenta accreta spectrum shows improved accuracy over conventional imaging methods, though generalizability challenges remain.

Retrospective cohort study linking ambient air pollutants to preeclampsia risk, identifying critical exposure windows and elevated vulnerability in assisted reproductive technology pregnancies.

Comparative study of preeclampsia outcomes in two Turkish centers reveals higher blood pressure, liver enzyme elevations, and complication rates in Şanlıurfa versus Bolu.

Explore tailored management strategies for familial hypercholesterolemia in pregnancy, addressing evidence gaps and the need for stage-specific, individualized approaches to optimize maternal and.

Retrospective study demonstrates that preeclampsia significantly increases long-term risk of hypertension, cardiovascular disease, obesity, and metabolic complications in women.

Echocardiographic assessment reveals progressive systolic and diastolic hemodynamic alterations in hypertensive pregnancy correlating with disease severity and adverse outcomes.

Retrospective validation of patient-initiated PreMA preconception screener demonstrates comparable predictive validity to established obstetric comorbidity indices for severe maternal morbidity.

Review of aspirin's pharmacological mechanisms and clinical evidence for low-dose therapy in pregnancy, emphasizing preeclampsia prevention and improved outcomes in high-risk populations.

Echocardiographic parameters independently predict adverse pregnancy outcomes in women aged 35+ with pregnancy-induced hypertension, with combined assessment achieving excellent discrimination.

Cross-sectional study of 312 pregnant women reveals progressive elevation of cardiac biomarkers including NT-proBNP and troponin-I across severity spectrum of hypertensive disorders.

CMD prevalence among pregnant women remains underrecognized; diagnostic methods and management approaches require pregnancy-specific validation and standardization to improve clinical outcomes.

Prospective Ugandan cohort (n=80) with PPCM: baseline severe LV dysfunction, 7.5% six-month mortality, 10% intracardiac thrombus, 46.3% LV recovery; two-thirds received bromocriptine.